These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 37330338)
1. NTRK fusions in solid tumours: what every pathologist needs to know. Nguyen MA; Colebatch AJ; Van Beek D; Tierney G; Gupta R; Cooper WA Pathology; 2023 Aug; 55(5):596-609. PubMed ID: 37330338 [TBL] [Abstract][Full Text] [Related]
2. Identifying patients with NTRK fusion cancer. Solomon JP; Benayed R; Hechtman JF; Ladanyi M Ann Oncol; 2019 Nov; 30(Suppl_8):viii16-viii22. PubMed ID: 31738428 [TBL] [Abstract][Full Text] [Related]
3. Identifying patients with NTRK fusion cancer. Solomon JP; Benayed R; Hechtman JF; Ladanyi M Ann Oncol; 2019 Nov; 30 Suppl 8():viii16-viii22. PubMed ID: 32223934 [TBL] [Abstract][Full Text] [Related]
4. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients. Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351 [TBL] [Abstract][Full Text] [Related]
5. Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland. Zhang W; Schmitz AA; Kallionpää RE; Perälä M; Pitkänen N; Tukiainen M; Alanne E; Jöhrens K; Schulze-Rath R; Farahmand B; Zong J Acta Oncol; 2024 Jul; 63():542-551. PubMed ID: 38967220 [TBL] [Abstract][Full Text] [Related]
6. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis. Hondelink LM; Schrader AMR; Asri Aghmuni G; Solleveld-Westerink N; Cleton-Jansen AM; van Egmond D; Boot A; Ouahoud S; Khalifa MN; Wai Lam S; Morreau H; Bovee JVMG; van Wezel T; Cohen D Eur J Cancer; 2022 Sep; 173():229-237. PubMed ID: 35933886 [TBL] [Abstract][Full Text] [Related]
7. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Marchiò C; Scaltriti M; Ladanyi M; Iafrate AJ; Bibeau F; Dietel M; Hechtman JF; Troiani T; López-Rios F; Douillard JY; Andrè F; Reis-Filho JS Ann Oncol; 2019 Sep; 30(9):1417-1427. PubMed ID: 31268127 [TBL] [Abstract][Full Text] [Related]
8. The oncogenic roles of NTRK fusions and methods of molecular diagnosis. Aref-Eshghi E; Lin F; Li MM; Zhong Y Cancer Genet; 2021 Nov; 258-259():110-119. PubMed ID: 34710798 [TBL] [Abstract][Full Text] [Related]
9. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD; Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007 [TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of cancers with NTRK gene fusions. Gatalica Z; Xiu J; Swensen J; Vranic S Mod Pathol; 2019 Jan; 32(1):147-153. PubMed ID: 30171197 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan. Nakata E; Osone T; Ogawa T; Taguchi T; Hattori K; Kohsaka S Cancer Med; 2024 Jun; 13(12):e7351. PubMed ID: 38925616 [TBL] [Abstract][Full Text] [Related]
12. Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review. Haddad R; Elisei R; Hoff AO; Liu Z; Pitoia F; Pruneri G; Sadow PM; Soares F; Turk A; Williams MD; Wirth LJ; Cabanillas ME JAMA Oncol; 2023 Aug; 9(8):1132-1141. PubMed ID: 37289450 [TBL] [Abstract][Full Text] [Related]
13. NTRK gene fusion testing and management in lung cancer. Repetto M; Chiara Garassino M; Loong HH; Lopez-Rios F; Mok T; Peters S; Planchard D; Popat S; Rudzinski ER; Drilon A; Zhou C Cancer Treat Rev; 2024 Jun; 127():102733. PubMed ID: 38733648 [TBL] [Abstract][Full Text] [Related]
14. Nefarious NTRK oncogenic fusions in pediatric sarcomas: Too many to Trk. Aepala MR; Peiris MN; Jiang Z; Yang W; Meyer AN; Donoghue DJ Cytokine Growth Factor Rev; 2022 Dec; 68():93-106. PubMed ID: 36153202 [TBL] [Abstract][Full Text] [Related]
15. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach. Hernandez S; Conde E; Molero A; Suarez-Gauthier A; Martinez R; Alonso M; Plaza C; Camacho C; Chantada D; Juaneda-Magdalena L; Garcia-Toro E; Saiz-Lopez P; Rojo F; Abad M; Boni V; Del Carmen S; Regojo RM; Sanchez-Frias ME; Teixido C; Paz-Ares L; Lopez-Rios F Arch Pathol Lab Med; 2024 Mar; 148(3):318-326. PubMed ID: 37270803 [TBL] [Abstract][Full Text] [Related]
16. [NTRK Gene Fusions and Treatment in NTRK Fusion-Positive Solid Cancers]. Fukuda M; Naito Y Gan To Kagaku Ryoho; 2022 Oct; 49(10):1048-1050. PubMed ID: 36281593 [TBL] [Abstract][Full Text] [Related]
17. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?]. Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719 [TBL] [Abstract][Full Text] [Related]
18. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586 [TBL] [Abstract][Full Text] [Related]